Lucid Diligence Brief: Innovent - Eli Lilly Global R&D Alliance
Lucid Diligence Brief: Innovent - Eli Lilly Global R&D Alliance…
Lucid Diligence Brief: Eli Lilly Pipeline Rationalization
Lucid Diligence Brief: Eli Lilly Pipeline Rationalization Professional…
Lucid Diligence Brief: Fortitude Biomedicines launch with $13M seed
Lucid Diligence Brief: Fortitude Biomedicines launch with $13M seed…
Lucid Diligence Brief: PAQ Therapeutics Series B for PT0511 pan-KRAS degrader
Lucid Diligence Brief: PAQ Therapeutics Series B for PT0511 pan-KRAS degrader…
Lucid Diligence Brief: Janux Therapeutics and Bristol Myers Squibb collaboration
Lucid Diligence Brief: Janux Therapeutics and Bristol Myers Squibb…
Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s GPC3-armored CAR-T
Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s…
Lucid Diligence Brief: Signet Therapeutics RMB 80 million Series A for organoids + AI in oncology
Lucid Diligence Brief: Signet Therapeutics RMB 80 million Series A for…
Lucid Diligence Brief: AstraZeneca to acquire Modella AI
Lucid Diligence Brief: AstraZeneca to acquire Modella AI Professional audiences…
Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics
Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics Professional…
Lucid Diligence Brief: Insilico Medicine × Servier oncology collaboration
Lucid Diligence Brief: Insilico Medicine × Servier oncology collaboration…
Lucid Diligence Brief: Zelgen × AbbVie option-to-license on alveltamig
Lucid Diligence Brief: Zelgen × AbbVie option-to-license on alveltamig…
Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics
Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics…